Literature DB >> 19689259

Phosphodiesterase 3 (PDE3): structure, localization and function.

Taku Murata1, Kasumi Shimizu, Kenichi Hiramoto, Toshiro Tagawa.   

Abstract

Cyclic adenosine 3'5'-monophosphate (cAMP) and cyclic guanosine 3'5'-monophosphate (cGMP) are critical intracellular messengers involved in transduction of signals generated by a wide variety of extracellular stimuli, including growth factors, cytokines, peptide hormones, light and neurotransmitters. These messengers modulate many fundamental biological processes, including myocardial contractility, platelet aggregation, vascular smooth muscle relaxation, proliferation and apoptosis, etc. Cyclic nucleotide phosphodiesterases (PDEs) catalyze the hydrolysis of cAMP and cGMP, and are important in regulating intracellular concentrations and biological actions of these signal-transducing molecules. These enzymes contain at least 11 highly regulated and structurally related gene families (PDE1-11). In this review, we will discuss some general information of PDEs and then focus on PDE3 gene family, including the molecular biology, structure, function and potential as therapeutic targets. Furthermore, we show the possibilities of PDE3 as therapeutic targets in malignant tumor cells and salivary gland.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19689259     DOI: 10.2174/187152509789105453

Source DB:  PubMed          Journal:  Cardiovasc Hematol Agents Med Chem        ISSN: 1871-5257


  4 in total

1.  Modulating the cyclic guanosine monophosphate substrate selectivity of the phosphodiesterase 3 inhibitors by pyridine, pyrido[2,3-d]pyrimidine derivatives and their effects upon the growth of HT-29 cancer cell line.

Authors:  Ashraf Hassan Abadi; Marwa Saeed Hany; Shimaa Awadain Elsharif; Amal Abdel Haleem Eissa; Bernard Dewayne Gary; Heather Nicole Tinsley; Gary Anthony Piazza
Journal:  Chem Pharm Bull (Tokyo)       Date:  2013       Impact factor: 1.645

2.  PDE3A inhibitor anagrelide activates death signaling pathway genes and synergizes with cell death-inducing cytokines to selectively inhibit cancer cell growth.

Authors:  Ran An; Jueyu Liu; Jing He; Fei Wang; Qing Zhang; Qiang Yu
Journal:  Am J Cancer Res       Date:  2019-09-01       Impact factor: 6.166

Review 3.  Phosphodiesterase type 5 and cancers: progress and challenges.

Authors:  Ines Barone; Cinzia Giordano; Daniela Bonofiglio; Sebastiano Andò; Stefania Catalano
Journal:  Oncotarget       Date:  2017-10-12

4.  Nimodipine vs. Milrinone - Equal or Complementary Use? A Retrospective Analysis.

Authors:  Jennifer Jentzsch; Svitlana Ziganshyna; Dirk Lindner; Helena Merkel; Simone Mucha; Stefan Schob; Ulf Quäschling; Karl-Titus Hoffmann; Robert Werdehausen; Dirk Halama; Khaled Gaber; Cindy Richter
Journal:  Front Neurol       Date:  2022-07-14       Impact factor: 4.086

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.